Researchers at the Department of Ophthalmology, at The Hebrew University of Jerusalem, have reported a new comprehensive analysis on Best disease patients, aimed to document… Read More »Mutations, analysis and genotype-phenotype results from the largest cohort of Best disease patients in the Israeli population and worldwide.
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the March 7th, 2024 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA… Read More »March 7th, 2024 “EURETINA-Brief”© Issue No. 287
Adverum Biotechnologies (NASDAQ: ADVM) has announced to sell approximately 106.25 million shares of its common stock at a price per share of $1.20 to institutional… Read More »Advernum Biotechnologies (NASDAQ: ADVM) has raised $127.5 million to progress gene therapy pipeline.
The MACUSTAR consortium, supported by the Innovative Medicines Initiative, has received a further support of funding from industry partners Bayer, Novartis and Roche, agreed to… Read More »The MACUSTAR consortium on AMD has received a further support of funding of €3M and an extension for work until 2027.
An international consortium of clinical researchers, led by Prof. Robert MacLaren, based in Oxford Eye Hospital, Oxford University Hospitals NHS Foundation Trust, UK, has reported… Read More »An international consortium report the largest, longest and comprehensive natural history study of choroideremia – a rare X-linked degenerative retinopathy.
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the February 14th, 2024 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA… Read More »February 14th, 2024 “EURETINA-Brief”© Issue No. 286
The European Commission has granted marketing authorization in the European Union (EU) for new Eylea 8 mg (aflibercept 8mg, 114.3 mg/ml solution for injection) for… Read More »The European Commission has approved aflibercept (8mg) for wet AMD, diabetic macular edema (DME) and diabetic retinopathy (DR).
Researchers at the Hawaiian Eye and Retina meeting in Maui has reported positive 6-month results for RGX-314, for the treatment of wet AMD, using a… Read More »Phase 2 interim data for RGX-314 treatment for wet AMD reports stable BCVA and CRT at six months.
Researchers at the Royal Victorian Eye and Ear Hospital, Victoria, Australia, have published a study on several retinal biomarkers using retinal vascular measurements, focused on… Read More »Retinal vascular measurements on all-cause and premature mortality reports analysis from the UK Biobank Study.
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the January 23rd, 2024 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA… Read More »January 23rd, 2024 “EURETINA-Brief”© Issue No. 285